Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALTO-207 · 1 trial · 1 indication
Montgomery Asberg Depression Rating Scale (MADRS) is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
| Arm | Type | Description |
|---|---|---|
| ALTO-207 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALTO-207 | DRUG | ALTO-207 BID |
| Placebo | DRUG | Matching Placebo |
Inclusion Criteria: * Male and female participants, ages 18 to 75 years, inclusive, at the time of signing the ICF. * Prior diagnosis of MDD without psychotic symptoms (in the current episode) and have confirmatory diagnosis of current MDD (moderate to severe). * Failure to respond (\<50% improveme...
ALTO-207 is an investigational small molecule being developed for the treatment of treatment-resistant depression (TRD). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
ALTO-207 targets the dopamine D3 receptor, a type of receptor involved in the central nervous system. By modulating this receptor, the drug aims to address symptoms of treatment-resistant depression, though its exact mechanism of action is still under investigation.
ALTO-207 is being developed by Alto Neuroscience, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol ANRO.
ALTO-207 is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by the FDA or any other regulatory agency.
ALTO-207 is being studied in a Phase 2 clinical trial with the identifier NCT07553637. This trial is recruiting participants with treatment-resistant depression and is expected to enroll 178 patients across the United States and United Kingdom.
No alternative names for ALTO-207 have been reported. It is a distinct investigational compound developed by Alto Neuroscience, Inc. for the treatment of treatment-resistant depression.